Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Upstream Bio, Inc.NASDAQ: UPB
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 45.1% from a year ago
Short-term investments stood at $197.86M at the end of Q1 FY2026, down 45.1% from a year earlier and down 17.5% from the prior quarter.
Context
- Short-term investments amounted to 62.2% of total assets at the end of Q1 FY2026, down 16.7 pp from a year earlier.
- Short-term investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -45.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 239.93M USD
- Year-over-year change
- +66.0%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 239.93M | +66.0% |
| FY2024 | 2024-12-31 | 144.56M | +72.1% |
| FY2023 | 2023-12-31 | 83.98M | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -45.1% is the lowest of 8, against a peer median of +45.5%.
- Short-term investments amounts to 62.2% of total assets for UPB, versus a peer median of 46.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $989.18M USD | +134.8% | +218.1% | 89.9% | |
| Jun 2026 | $789.75M USD | +45.5% | -17.8% | 81.6% | |
| Mar 2026 | $561.97M USD | +20.0% | — | 53.9% | |
| Sep 2026 | $528.04M USD | +344.4% | -31.8% | 67.1% | |
| Mar 2026 | $241.29M USD | -36.0% | -23.9% | 31.8% | |
| Mar 2026 | $221.17M USD | -39.0% | -12.1% | 46.8% | |
| Mar 2026 | $216.98M USD | +87.3% | — | 29.0% | |
UPBUpstream Bio, Inc. | Mar 2026 | $197.86M USD | -45.1% | — | 62.2% |
| Sep 2026 | €0 EUR | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UPB) | — | +45.5% | -17.8% | 46.8% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.